A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications
Public ClinicalTrials.gov record NCT00856544. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 3, Randomized, Double Blind, Placebo Controlled Study Of The Safety And Efficacy Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background DMARDS
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase 3 study is intended to provide evidence that CP-690,550 dosed 5 mg BID and 10 mg BID is safe and effective when used in combination with a variety of traditional disease modifying antirheumatic drugs in adult patients with rheumatoid arthritis. It is intended to confirm the benefits of CP-690,550 in improving signs and symptoms and physical function that were observed in the Phase 2 rheumatoid arthritis studies.
Study identification
- NCT ID
- NCT00856544
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 795 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2009 (Type not available)
- Primary completion
- Jan 2011 (Actual)
- Completion
- Jan 2011 (Actual)
- Last update posted
- Jan 10, 2013
2009 – 2011
United States locations
- U.S. sites
- 46
- U.S. states
- 22
- U.S. cities
- 44
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Huntsville | Alabama | 35801 | — |
| Pfizer Investigational Site | Jonesboro | Arkansas | 72401 | — |
| Pfizer Investigational Site | Palo Alto | California | 94304 | — |
| Pfizer Investigational Site | Stanford | California | 94305 | — |
| Pfizer Investigational Site | Boulder | Colorado | 80304 | — |
| Pfizer Investigational Site | Denver | Colorado | 80206 | — |
| Pfizer Investigational Site | Danbury | Connecticut | 06810 | — |
| Pfizer Investigational Site | Hamden | Connecticut | 06518 | — |
| Pfizer Investigational Site | Trumbull | Connecticut | 06611 | — |
| Pfizer Investigational Site | New Port Richey | Florida | 34652 | — |
| Pfizer Investigational Site | Ocala | Florida | 34474 | — |
| Pfizer Investigational Site | Plantation | Florida | 33324 | — |
| Pfizer Investigational Site | Port Richey | Florida | 34668 | — |
| Pfizer Investigational Site | Tamarac | Florida | 33321 | — |
| Pfizer Investigational Site | Tampa | Florida | 33613 | — |
| Pfizer Investigational Site | Decatur | Georgia | 30033 | — |
| Pfizer Investigational Site | Marietta | Georgia | 30060 | — |
| Pfizer Investigational Site | Maywood | Illinois | 60153 | — |
| Pfizer Investigational Site | Oakbrook Terrace | Illinois | 60181 | — |
| Pfizer Investigational Site | Rockford | Illinois | 61103-3692 | — |
| Pfizer Investigational Site | Springfield | Illinois | 62702 | — |
| Pfizer Investigational Site | Springfield | Illinois | 62703 | — |
| Pfizer Investigational Site | Vernon Hills | Illinois | 60061 | — |
| Pfizer Investigational Site | Evansville | Indiana | 47714 | — |
| Pfizer Investigational Site | Indianapolis | Indiana | 46227 | — |
| Pfizer Investigational Site | Wichita | Kansas | 67203 | — |
| Pfizer Investigational Site | Lexington | Kentucky | 40505 | — |
| Pfizer Investigational Site | Leominster | Massachusetts | 01453 | — |
| Pfizer Investigational Site | Worcester | Massachusetts | 01605 | — |
| Pfizer Investigational Site | Edina | Minnesota | 55435 | — |
| Pfizer Investigational Site | Lincoln | Nebraska | 68516 | — |
| Pfizer Investigational Site | Albany | New York | 12206 | — |
| Pfizer Investigational Site | Orchard Park | New York | 14127 | — |
| Pfizer Investigational Site | Rochester | New York | 14618 | — |
| Pfizer Investigational Site | Asheville | North Carolina | 28801 | — |
| Pfizer Investigational Site | Charlotte | North Carolina | 28210 | — |
| Pfizer Investigational Site | Bethlehem | Pennsylvania | 18015 | — |
| Pfizer Investigational Site | Wyomissing | Pennsylvania | 19610 | — |
| Pfizer Investigational Site | Greenville | South Carolina | 29601 | — |
| Pfizer Investigational Site | Knoxville | Tennessee | 37909 | — |
| Pfizer Investigational Site | Austin | Texas | 78705 | — |
| Pfizer Investigational Site | Dallas | Texas | 75235 | — |
| Pfizer Investigational Site | Seattle | Washington | 98133 | — |
| Pfizer Investigational Site | Tacoma | Washington | 98405-2308 | — |
| Pfizer Investigational Site | Tacoma | Washington | 98405 | — |
| Pfizer Investigational Site | Clarksburg | West Virginia | 26301 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 87 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00856544, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 10, 2013 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00856544 live on ClinicalTrials.gov.